Department of Basic Medical Sciences, School of Medicine, Hunan Normal University, Changsha, China.
Hunan Gynecological Tumor Clinical Research Center; Hunan Key Laboratory of Cancer Metabolism; Hunan Cancer Hospital, and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
J Transl Med. 2024 Aug 21;22(1):778. doi: 10.1186/s12967-024-05583-z.
The advent of polyadenosine diphosphate ribose polymerase inhibitors (PARPi) has brought about significant changes in the field of ovarian cancer treatment. However, in 2022, Rucaparib, Olaparib, and Niraparib, had their marketing approval revoked for third-line and subsequent therapies due to an increased potential for adverse events. Consequently, the exploration of new treatment modalities remains imperative. Recently, the integration of PARPi with immune checkpoint inhibitors (ICIs) has emerged as a potential remedy option within the context of ovarian cancer. This article offers a comprehensive examination of the mechanisms and applications of PARPi and ICIs in the treatment of ovarian cancer. It synthesizes the existing evidence supporting their combined use and discusses key considerations that merit attention in ongoing development efforts.
聚腺苷二磷酸核糖聚合酶抑制剂（PARPi）的出现给卵巢癌治疗领域带来了重大变化。然而，2022 年，由于不良反应风险增加，鲁卡帕尼、奥拉帕利和尼拉帕利的三线及后续治疗的药物上市许可被撤销。因此，探索新的治疗方法仍然至关重要。最近，PARPi 与免疫检查点抑制剂（ICIs）的联合应用在卵巢癌治疗中成为一种潜在的治疗选择。本文全面研究了 PARPi 和 ICIs 在卵巢癌治疗中的作用机制和应用，综合了支持联合应用的现有证据，并讨论了在当前开发工作中值得关注的关键问题。
